ABBI Abraxis Bioscience (MM)

On November 8, 2007, the Company also set forth materials on its website (www.abraxisbio.com) relating to the hospital-based business that will be operated by APP Pharmaceuticals, Inc. and its subsidiary APP Pharmaceuticals, LLC (“New APP”) following the previously announced spin-off of the Company’s proprietary business, that includes historical financial results of the hospital-based business of New APP on a stand alone basis for the twelve months ended December 31, 2007 and the six months ended June 30, 2007. The unaudited consolidated statements of income of New APP were derived from the elimination of the historical results of operations of the business of New Abraxis, Inc. (to be renamed Abraxis BioScience following the spin-off transaction) (“New Abraxis”) as reflected in its Form 10 Registration Statement that was filed with the SEC on November 2, 2007, from the historical results of operations of the Company previously filed with the SEC on Form 10-K for the fiscal year ended December 31, 2006 and on Form 10-Q for the six months ended June 30, 2007 (together with comparisons of the corresponding year to date period in the previous fiscal year). In addition, the Company provided estimates of the financial results for the three and nine months periods ended September 30, 2007, the three and twelve months period ended December 31, 2007 and the LTM ended September 30, 2007. These projected unconsolidated statements of income were prepared using reasonable assumptions based on current information, however there can be no assurance that these estimates of future results will be realized, and estimates are subject to risks and uncertainties, many of which are not within our control. See “Forward-Looking Statements” set forth in the materials. The Company does not undertake any obligation to update publicly any forward-looking statement, including, without limitation, any estimate regarding revenues or earnings, whether as a result of the receipt of new information, future events or otherwise. A copy of the material is furnished (but not filed) as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

In addition to providing the derived historical financial results for New APP, the Company presented a non-GAAP financial measure of adjusted EBITDA for New APP. Adjusted EBITDA for this purpose is defined as the derived New APP net income excluding the impact stock-based compensation expense, minority interests, loss on early retirement of debt, Melrose Park revalidation, ERP implementation, non-recurring legal costs, separation-related

costs, and pre-launch costs associated with the Puerto Rico manufacturing facility. The Company believes that its presentation of the Adjusted EBITDA for New APP provides useful supplementary information to investors in understanding the underlying operating performance of New APP following the spin-off transaction and facilitates additional analysis by investors. The Company also uses this Adjusted EBITDA for New APP internally for operating, budgeting and financial planning purposes. The Company also believes that its presentation of the Adjusted EBITDA for New APP can assist management and investors in assessing the financial operating performance and underlying strength of the core business of New APP. The Adjusted EBITDA presented by the Company may not be comparable to similarly titled measures reported by other companies. The Adjusted EBITDA is in addition to, and not a substitute for or superior to, measures of financial performance calculated in accordance with GAAP. Reconciliation of the Company’s GAAP net income for the twelve months ended December 31, 2007 and the six months ended June 30, 2007 to Adjusted EBITDA for New APP for those periods is included in the presentation.